Evan A. Stein

10.1k citations

59 papers · 4.7k indexed · 3 hit papers · h-index 27

Impact in

Endocrinology, Diabetes and Metabolism top 0.5%
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Menopause: Health Impacts and Treatments
Surgery top 1%
- Lipoproteins and Cardiovascular Health

Papers in

Surgery 50
- Lipoproteins and Cardiovascular Health 49
Endocrinology, Diabetes and Metabolism 17
- Diabetes, Cardiovascular Risks, and Lipoproteins 15

Co-authors: Christie M. Ballantyne Peter M. Laskarzewski Michael Lane Michael H. Davidson Harold Bays Jonathan L. Isaacsohn John J.P. Kastelein Marian C. Limacher
Journals: The American Journal of Cardiology (11 papers)Journal of the American College of Cardiology (8 papers)Circulation (3 papers)American Heart Journal (3 papers)Atherosclerosis (3 papers)
Partner nations: United States United Kingdom Canada

In The Last Decade

Evan A. Stein

53 papers receiving 4.5k citations

Hit Papers

align trajectories log scale

A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia 2014 · 553 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2014 New England Journal of Medicine
2011 The Lancet
2003 JAMA

Peers

Countries citing papers authored by Evan A. Stein

Since Specialization

Citations

This map shows the geographic impact of Evan A. Stein's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Evan A. Stein with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Evan A. Stein more than expected).

Fields of papers citing papers by Evan A. Stein

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Evan A. Stein. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Evan A. Stein. The network helps show where Evan A. Stein may publish in the future.

Co-authors

The 25 scholars most cited alongside Evan A. Stein, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Evan A. Stein Line = papers co-authored together Evan A. Stein links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	A POOLED SAFETY ANALYSIS OF OVER 6000 PATIENTS FROM DOUBLE-BLIND AND OPEN-LABEL EXTENSION STUDIES WITH EVOLOCUMAB Journal of the American College of Cardiology ·Peter P. Tóth, Olivier Descamps, Jacques Genest, Naveed Sattar, David Preiss, Ricardo Dent, C. Stephen Djedjos, Mia Zeric, Michelle Geller, Ransi Somaratne, Scott M. Wasserman, Evan A. Stein	2016	3
2	CLINICAL EQUIVALENCE OF EVOLOCUMAB 140 MG EVERY TWO WEEKS AND 420 MG MONTHLY DOSING REGIMENS: A POOLED ANALYSIS OF 3146 PATIENTS IN PHASE 3 STUDIES Journal of the American College of Cardiology ·Evan A. Stein, Michael J. Koren, Narimon Honarpour, Christopher E. Kurtz, Jingyuan Yang, Scott M. Wasserman, Frederick J. Raal	2015	5
3	A COMPREHENSIVE SAFETY ANALYSIS OF 6026 PATIENTS FROM PHASE 2 AND 3 SHORT AND LONG TERM CLINICAL TRIALS WITH EVOLOCUMAB (AMG 145) Journal of the American College of Cardiology ·Peter P. Tóth, Naveed Sattar, Jacques Genest, Olivier Descamps, Ricardo Dent, C. Stephen Djedjos, Jason C. Legg, Scott M. Wasserman, Evan A. Stein	2015	8
4	Abstract 12621: Efficacy and Tolerability of Long-Term Treatment With AMG 145 in Patients With Statin Intolerance Circulation ·Evan A. Stein, Ransi Somaratne, Maria Paola Ferro, Fernando Civeira, Danielle Sullivan, Gerald F. Watts, Robert Weiss, Leon A. Simons, 大橋善治, Allen Xue, Russell Scott, Scott M. Wasserman, Matti J. Tikkanen	2013	2
5	Efficacy and Safety of Eicosapentaenoic Acid Ethyl Ester (AMR101) Therapy in Statin-Treated Patients With Persistent High Triglycerides (from the ANCHOR Study) The American Journal of Cardiology ·Christie M. Ballantyne, Harold Bays, John J.P. Kastelein, Evan A. Stein, Jonathan L. Isaacsohn, Rene A. Braeckman, Paresh N. Soni	2012	256
6	Abstract 15071: AMR101 Lowers Triglycerides, Atherogenic Lipoprotein, Phospholipase A2, and High-sensitivity C-reactive Protein Levels in Patients With High Triglycerides and on Background Statin Therapy (the ANCHOR Study) Circulation ·Christie M. Ballantyne, Harold Bays, John J.P. Kastelein, Evan A. Stein, Jonathan L. Isaacsohn, Rene A. Braeckman, Paresh N. Soni	2011	3
7	Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial The Lancet ·Zahi A. Fayad, Venkatesh Mani, Mark Woodward, David Kallend, Markus Abt, Tracy Burgess, Valentı́n Fuster, Christie M. Ballantyne, Evan A. Stein, Jean‐Claude Tardif, James H.F. Rudd, Michael E. Farkouh, Ahmed Tawakol Hit paper breakdown →	2011	377
8	Efficacy and tolerability of adding prescription Omega-3 fatty acids 4 g/d to Simvastatin 40 mg/d in hypertriglyceridemic patients: An 8-week, randomized, double-blind, placebo-controlled study Clinical Therapeutics ·Michael H. Davidson, Evan A. Stein, Harold Bays, Kevin C. Maki, Ralph T. Doyle, Robert A. Shalwitz, Christie M. Ballantyne, Henry N. Ginsberg	2007	295
9	Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY (MERCURY) II American Heart Journal ·Christie M. Ballantyne, Marcelo Chiara Bertolami, Jinye Wu, M. Okuyama, Evan A. Stein, Pierre Théroux, Robert Weiss, Valerie A. Cain, Joel S. Raichlen	2006	87
10	Safety of rosuvastatin The American Journal of Cardiology ·James Shepherd, Donald B. Hunninghake, Evan A. Stein, John J.P. Kastelein, Susan S. Harris, John Pears, Howard G. Hutchinson	2004	115
11	Ezetimibe coadministered with atorvastatin compared to atorvastatin alone in the attainment of low-density lipoprotein goals among high-risk patients with hypercholesterolemia Journal of the American College of Cardiology ·Evan A. Stein, Steen Stender, Pedro Mata, 宏小山, Lorenzo Melani, Philip T. Sager, M Sangumea, Ramachandran Suresh, Enrico P. Veltri	2003	1
12	Effect of Estrogen Plus Progestin on Stroke in Postmenopausal Women JAMA ·Sylvia Wassertheil‐Smoller, Susan L. Hendrix, Marian C. Limacher, Gerardo Heiss, Charles Kooperberg, Alison E. Baird, Theodore A. Kotchen, J. David Curb, Henry R. Black, Jacques E. Rossouw, Aaron K. Aragaki, Monika Safford, Evan A. Stein, Somchai Laowattana, W. Jerry Mysiw, 祐弘正 Hit paper breakdown →	2003	827
13	The power of statins: Aggressive lipid lowering Clinical Cardiology ·Evan A. Stein	2003	34
14	Efficacy of rosuvastatin 10 mg in patients with the metabolic syndrome The American Journal of Cardiology ·Christie M. Ballantyne, Evan A. Stein, Rodolfo Paoletti, Harry Southworth, James W. Blasetto	2003	36
15	Management of dyslipidemia in the high-risk patient American Heart Journal ·Evan A. Stein	2002	21
16	Apolipoprotein E genotypes and response of plasma lipids and progression–regression of coronary atherosclerosis to lipid-lowering drug therapy Journal of the American College of Cardiology ·Christie M. Ballantyne, J.Alan Herd, Evan A. Stein, Laura Ferlic, J. Kay Dunn, Antonio M. Gotto, Ali J. Marian	2000	68
17	Efficacy and Safety of Lovastatin in Adolescent Males With Heterozygous Familial Hypercholesterolemia JAMA ·Evan A. Stein, D. Roger Illingworth, Peter O. Kwiterovich, Chris A. Liacouras, Martti A. Siimes, Mark Z. Jacobson, Thomas Brewster, Paul N. Hopkins, Michael H. Davidson, Kevin J. Graham, Frederick W. Arensman, Robert H. Knopp, Carlos A. Dujovne, Christine L. Williams, Jonathan L. Isaacsohn, Gurkirat Singh, Peter M. Laskarzewski, A Aldis, Glenn J. Gormley	1999	196
18	Cerivastatin Drugs ·Evan A. Stein	1998	1
19	Comparison of Statins in Hypertriglyceridemia The American Journal of Cardiology ·Evan A. Stein, Michael Lane, Peter M. Laskarzewski	1998	309
20	Effects of lovastatin therapy on plasminogen activator inhibitor-1 antigen levels The American Journal of Cardiology ·Jonathan L. Isaacsohn, Silvia López, Kathy Hebbeler, Janice A. Davey, Robert Vicar, Omar L. Valladares, Ellen Liskov, Evan A. Stein, H BLACK	1994	50

About Evan A. Stein

Evan A. Stein is a scholar working on Surgery, Endocrinology, Diabetes and Metabolism, Cancer Research, Computational Theory and Mathematics and Economics and Econometrics, having authored 59 papers that have together received 4.7k indexed citations. Recurring topics across this work include Lipoproteins and Cardiovascular Health (49 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (15 papers), Cancer, Lipids, and Metabolism (10 papers), Pharmaceutical Economics and Policy (8 papers), Computational Drug Discovery Methods (7 papers), Health Systems, Economic Evaluations, Quality of Life (7 papers), Lipid metabolism and disorders (4 papers) and Fatty Acid Research and Health (4 papers). The work is most often cited by research in Endocrinology, Diabetes and Metabolism (1.7k citations), Surgery (2.6k citations), Cancer Research (616 citations), Cardiology and Cardiovascular Medicine (818 citations) and Nutrition and Dietetics (448 citations). Evan A. Stein has collaborated with scholars based in United States, United Kingdom and Canada. Frequent co-authors include Christie M. Ballantyne, Peter M. Laskarzewski, Michael Lane, Michael H. Davidson, Harold Bays, Jonathan L. Isaacsohn, John J.P. Kastelein, Marian C. Limacher, Monika Safford and Alison E. Baird. Their work appears in journals such as The American Journal of Cardiology, Journal of the American College of Cardiology, Circulation, American Heart Journal and Atherosclerosis.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact